Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
 |
Food and Drug Administration - August 13, 2007
Richard Klein & Kimberly Struble
Abbott has sent out a Dear Healthcare Provider letter highlighting important information about Kaletra dosing for children. A pdf copy of the letter and the accompanying dosing guidelines for children receiving the recommended dose of lopinavir/ritonavir using Kaletra Oral Solution is attached.
The FDA website has a pediatric HIV drug page that provides additional information about pediatric dosing, at http://www.fda.gov/oashi/aids/pedlbl.html
Richard Klein | Office of Special Health Issues | Food and Drug Administration
Kimberly Struble | Division of Antiviral Drug Products | Food and Drug Administration
070813
FD070804
SOURCE: Food and Drug Administration (FDA).
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .
